Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study. HARMONIA SOLTI-2101 / AFT-58
- Citation:
- Journal of Clinical Oncology vol 41 (16 suppl) TPS1125
- Meeting Instance:
- ASCO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Novartis
- Grants:
- Corr. Author:
- Authors:
- Tomas Pascual Daniel G. Stover Astrid Thuerigen Rodrigo Sanchez Bayona Charles M. Perou Eva Ciruelos ANA Casas Patricia Spears Estelle Roux Fei Su Huilin Hu Yen-Shen Lu Sarah M. Tolaney Ann Partridge Guillermo Villacampa Juan Manuel Ferrero-Cafiero Lisa Carey Aleix Prat
- Networks:
- LAPS-MA036, LAPS-NC007, LAPS-OH007
- Study
- AFT-58
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: